S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?

Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis

$1.16
-0.06 (-4.94%)
(As of 04/15/2024 ET)
Today's Range
$1.14
$1.22
50-Day Range
$1.13
$1.66
52-Week Range
$0.62
$4.87
Volume
810,557 shs
Average Volume
1.66 million shs
Market Capitalization
$132.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

Karyopharm Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
390.6% Upside
$5.67 Price Target
Short Interest
Bearish
19.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$198,175 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.19) to ($1.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.84 out of 5 stars

Medical Sector

210th out of 928 stocks

Pharmaceutical Preparations Industry

84th out of 434 stocks

KPTI stock logo

About Karyopharm Therapeutics Stock (NASDAQ:KPTI)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

KPTI Stock Price History

KPTI Stock News Headlines

KPTI Apr 2024 5.000 call
A.I. Stocks Recommended By Investment Analyst Who Beat 15,000+ Others
An under-the-radar investment analyst who beat out 15,000+ other experts in 2020... Who regularly recommends stocks that go up 100%... 500%... 1,000%... Is now recommending THESE A.I. stocks.
KPTI Apr 2024 1.500 put
A.I. Stocks Recommended By Investment Analyst Who Beat 15,000+ Others
An under-the-radar investment analyst who beat out 15,000+ other experts in 2020... Who regularly recommends stocks that go up 100%... 500%... 1,000%... Is now recommending THESE A.I. stocks.
Q4 2023 Karyopharm Therapeutics Inc Earnings Call
Karyopharm Therapeutics Inc. Q4 Loss misses estimates
Karyopharm Therapeutics's Earnings: A Preview
KPTI Mar 2024 1.000 put
KPTI Mar 2024 1.500 call
See More Headlines
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/15/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KPTI
Fax
N/A
Employees
325
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.67
High Stock Price Target
$10.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+370.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-143,100,000.00
Pretax Margin
-97.77%

Debt

Sales & Book Value

Annual Sales
$146.03 million
Book Value
($1.19) per share

Miscellaneous

Free Float
111,247,000
Market Cap
$138.66 million
Optionable
Optionable
Beta
0.03
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Richard A. Paulson M.B.A. (Age 57)
    President, CEO & Director
    Comp: $1.36M
  • Dr. Sharon Shacham M.B.A. (Age 54)
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
    Comp: $1.4M
  • Mr. Michael P. Mason CPAMr. Michael P. Mason CPA (Age 49)
    M.B.A., Executive VP, CFO & Treasurer
    Comp: $681.59k
  • Mr. Michael J. Mano J.D. (Age 47)
    Senior VP, General Counsel & Secretary
    Comp: $625.08k
  • Ms. Sohanya Cheng M.B.A. (Age 41)
    Executive VP & Chief Commercial Officer
    Comp: $664.3k
  • Mr. Stuart Poulton
    Executive VP & Chief Development Officer
  • Dr. Mansoor Raza Mirza M.D. (Age 63)
    Clinical Consultant, Member of Scientific Advisory Board & Independent Director
    Comp: $150k
  • Mr. Cameron Peters (Age 64)
    Vice President of Finance, Assistant Treasurer & Principal Accounting Officer
  • Ms. Elhan Webb C.F.A.
    Senior Vice President of Investor Relations
  • Mr. James Accumanno J.D.
    Chief Compliance Officer

KPTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KPTI shares.
View KPTI analyst ratings
or view top-rated stocks.

What is Karyopharm Therapeutics' stock price target for 2024?

5 Wall Street analysts have issued 1 year price targets for Karyopharm Therapeutics' stock. Their KPTI share price targets range from $3.00 to $10.00. On average, they anticipate the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 390.6% from the stock's current price.
View analysts price targets for KPTI
or view top-rated stocks among Wall Street analysts.

How have KPTI shares performed in 2024?

Karyopharm Therapeutics' stock was trading at $0.8650 at the start of the year. Since then, KPTI shares have increased by 33.5% and is now trading at $1.1550.
View the best growth stocks for 2024 here
.

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KPTI earnings forecast
.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.07. The firm earned $33.75 million during the quarter, compared to analyst estimates of $33.50 million. During the same quarter in the previous year, the company earned ($0.43) earnings per share.

What ETF holds Karyopharm Therapeutics' stock?

iShares Genomics Immunology and Healthcare ETF holds 391,728 shares of KPTI stock, representing 0.49% of its portfolio.

What guidance has Karyopharm Therapeutics issued on next quarter's earnings?

Karyopharm Therapeutics updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $140.0 million-$160.0 million, compared to the consensus revenue estimate of $152.0 million.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KPTI) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners